Amanda Maggart, PA
Physician Assistant · Worthington, OHNPI 1629356191
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $103,560 of the $163,603 with a category attached, or 63.3%. Medtronic accounts for 83.1% of it on its own, with 35 other manufacturers making up the rest. 2025 is the largest year on record at $70,386, more than ten times the $6,613 reported in 2021. Among physician assistant clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 882 payments — averaging $185.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$136K
- Sumitomo Pharma America, Inc.$18K
- Urovant Sciences Inc$4K
- Dendreon Pharmaceuticals LLC$1K
- Astellas Pharma US Inc$574
- Urogen Pharma, Inc.$505
- plus $4K from 30 others
Across 2 payments — averaging $105.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$210
What the payments were for
- Consulting fees$2,7072%
- Speaking & faculty fees$103,56063%
- Travel & lodging$39,91424%
- Food & beverage$17,15510%
- Education$2670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 552 | $135,879 |
| Sumitomo Pharma America, Inc. | 100 | $17,518 |
| Urovant Sciences Inc | 21 | $3,775 |
| Dendreon Pharmaceuticals LLC | 32 | $1,246 |
| Astellas Pharma US Inc | 29 | $574 |
| Urogen Pharma, Inc. | 14 | $505 |
| Johnson & Johnson | 14 | $468 |
| Bayer | 5 | $453 |
| Pfizer | 20 | $381 |
| Boston Scientific | 4 | $352 |
| Endo USA, Inc. | 7 | $349 |
| Endo Pharmaceuticals Inc. | 9 | $253 |
| Progenics Pharmaceuticals, Inc. | 8 | $224 |
| Novartis | 12 | $203 |
| Olympus America Inc. | 4 | $198 |
| Janssen Scientific Affairs, LLC | 2 | $186 |
| AstraZeneca | 6 | $152 |
| Teleflex LLC | 1 | $145 |
| Myovant Sciences Inc. | 6 | $119 |
| Amgen | 6 | $108 |
| Tolmar Pharmaceuticals, Inc. | 4 | $71 |
| Tolmar, Inc. | 3 | $51 |
| Merck | 3 | $50 |
| Sanofi | 2 | $48 |
| Accord Healthcare, Inc. | 3 | $43 |
| Verity Pharmaceuticals Inc. | 3 | $42 |
| Convatec Inc. | 1 | $28 |
| Ferring Pharmaceuticals Inc. | 2 | $27 |
| Clarus Therapeutics Inc. | 2 | $26 |
| Antares Pharma, Inc. | 1 | $24 |
| Immunitybio, Inc. | 1 | $24 |
| Axonics, Inc. | 1 | $20 |
| Blue Earth Diagnostics | 1 | $19 |
| Coloplast | 1 | $16 |
| Pharmaand GmbH | 1 | $14 |
| Procept Biorobotics Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$121,289
- GEMTESA$19,451
- INTELLIS ADAPTIVESTIM$557
- PROVENGE$422
- Xofigo$392
- AKEEGA$366
- JELMYTO$270
- Erleada$254
- XIAFLEX$254
- GENERAL ERECTILE DYSFUNCTION$149
- UroLift$145
- iTIND System$144
- GENERAL BPH$117
How this compares
$163,603 in reported general payments places this provider in the 95th percentile of 4,098 physician assistant providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 146 | $100,212 |
| GemtesaVibegron | 35 | $33,217 |
| Methenamine Hippurate | 123 | $8,814 |
| Estradiol | 43 | $2,629 |
| Oxybutynin Chloride ErOxybutynin Chloride | 111 | $1,924 |
| Tamsulosin Hcl | 138 | $1,502 |
| Solifenacin Succinate | 29 | $1,389 |
| Testosterone Cypionate | 28 | $973 |
| NitrofurantoinNitrofurantoin Macrocrystal | 30 | $963 |
| Cabergoline | 11 | $638 |
| Oxybutynin Chloride | 27 | $545 |
| Trimethoprim | 13 | $535 |
| Cephalexin | 48 | $476 |
| Cefdinir | 20 | $354 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 33 | $344 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $574 | $100,212146 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $17,518 | $33,21735 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,098 physician assistant providers in Ohio.
Other physician assistant in Worthington
- Steven WurzelbacherCincinnati$309K
- Emily AnkromDayton$192K
- Megan SevillaMayfield Heights$132K
- Erin StrculaBelpre$106K
- Sarah LaubNew Albany$100K
- Jessica RhominskiCanal Winchester$78K
- Brook GramBeloit$52K
- Alison FleigToledo$48K
- Alicia PerkinsColumbus$44K
- Julie WestColumbus$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.